Camp4 Therapeutics (CAMP) Equity Average (2023 - 2026)

Camp4 Therapeutics' Equity Average history runs 4 years deep, the most recent figure standing at $39.3 million for Q1 2026.

• In Q1 2026, Equity Average fell 31.48% year-over-year to $39.3 million; the TTM figure through Mar 2026 stood at $39.3 million (down 31.48% YoY), while the FY2025 annual figure was $55.4 million, up 282.96% from the prior year.
• Equity Average came in at $39.3 million for Q1 2026 at Camp4 Therapeutics, down from $53.2 million in the prior quarter.
• In the past five years, Equity Average ranged from a high of $57.4 million in Q1 2025 to a low of -$153.0 million in Q3 2024.
• A 4-year average of -$34.4 million and a median of -$4.3 million in 2024 frame the typical range for Equity Average.
• Across the five-year window, Equity Average jumped 211.0% in 2025 and slumped 31.48% in 2026, its largest moves.
• Camp4 Therapeutics' Equity Average stood at -$117.6 million in 2023, then soared by 59.27% to -$47.9 million in 2024, then surged by 211.0% to $53.2 million in 2025, then slipped by 26.1% to $39.3 million in 2026.
• According to Business Quant data, Equity Average over the past three periods registered $39.3 million, $53.2 million, and $49.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison